BNTC Benitec Biopharma Inc.
Executive Summary
Four institutional investors, primarily mega-passive managers, increased their BNTC positions in Q4 2025, with aggregate holdings rising $2.3M to $5.0M. The buying is dominated by passive rebalancing (BofA, Wells Fargo, Morgan Stanley) and one asset manager (Ameriprise Financial), suggesting no active catalyst-driven thesis. Historical calibration shows prior bullish reports on BNTC underperformed at T+20, and the cluster's small absolute dollar amounts limit material impact.
Key Financial Metrics
Institutional Positions
Net institutional flow: $2.3M
▲ Buyers (4)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Ameriprise Financial | ADD | +81.8% | $3.8M | $1.6M |
| Morgan Stanley | DOUBLED | +264.9% | $792.0K | $566.0K |
| Wells Fargo | ADD | +78.1% | $219.0K | $91.0K |
| BofA | ADD | +60.4% | $163.0K | $57.0K |
Actionable Insight
The cluster is too small in absolute dollar terms ($2.3M net buying on a $357M market cap) and too dominated by passive managers to signal a strong catalyst. Monitor for active fund 13F filings (e.g., healthcare-dedicated funds) or insider buying for a more conviction-driven signal. The historical underperformance of prior bullish BNTC reports suggests caution.
Key Facts
- 4 institutional buyers added $2.3M net, bringing total disclosed holdings to $5.0M
- No institutional sellers in the cluster
- 3 of 4 buyers are mega-passive managers (BofA, Wells Fargo, Morgan Stanley) — likely index rebalancing, not active conviction
- Ameriprise Financial (asset manager) made the largest dollar addition at $1.6M, increasing position by 81.8%
- Morgan Stanley nearly tripled its position (+264.9%), but from a small base ($226K → $792K)
- Prior bullish reports on BNTC averaged -8.49% at T+20 with 0% win rate over 2 settled reports
Financial Impact
4 institutions accumulated $2.3M in new BNTC holdings, bringing total disclosed positions to $5.0M. No selling activity.
Risk Factors
- 45-day 13F reporting lag means positions may have already been unwound
- Passive buying provides no fundamental thesis — may reflect index rebalancing, not stock-specific conviction
- Prior bullish reports on BNTC have underperformed at T+20 (0% win rate, -8.49% average return)
- Small absolute dollar amounts limit price impact potential
Market Snapshot
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-BNTC-2025-Q4 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $10.90 awaiting T+5 | awaiting T+5 | — | — |
|
Jun 11, 2026
2d ago
|
Institutional Cluster
| $10.40 awaiting T+5 | awaiting T+5 | — | — |
|
May 14, 2026
4w ago
|
8-K
| $11.85 $11.36 | ▼ −4.13% | ▼ −3.42% | — |
|
May 14, 2026
4w ago
|
Press Release
| $11.85 $11.36 | ▼ −4.13% | ▼ −3.42% | — |
|
Mar 10, 2026
13w ago
|
Press Release
| $12.27 $11.75 | ▼ −4.24% | ▼ −3.33% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access